Detailed description of the main functions, efficacy and applicable symptoms of ensifentrine-Ohtuvayre

Ensifentrine (Ensifentrine, trade name Ohtuvayre) is a new dual-action respiratory drug that also contains phosphodiesterase 3 (PD E3) inhibition and β2 receptor agonism, mainly used for the treatment of chronic obstructive pulmonary disease (COPD). Its unique dual mechanism enables the drug to both expand airway smooth muscles and reduce airway inflammation, thereby improving respiratory function and symptoms and improving patients' quality of life. Exefentine provides more comprehensive airway improvement than traditional single-mechanism bronchodilators.

Clinical studies have shown that ensefentin can significantly improve lung function indicators in patients with COPD, such as forced expiratory volume (FEV1), peak expiratory flow (PEF), etc., while reducing symptoms such as dyspnea, cough and sputum production. For patients with COPD who smoke for a long time or have airway inflammation, the anti-inflammatory effect of ensefentine can reduce airway structural damage and delay the progression of the disease. In addition, the drug can act on the airways through local inhalation, reducing the risk of systemic adverse reactions.

The indications of Ohtuvayre mainly include long-term maintenance treatment of chronic obstructive pulmonary disease, especially for patients with moderate to severe COPD or those with poor efficacy of traditional inhaled bronchodilators. In clinical use, the drug can be used alone or in combination with inhaled corticosteroids or other bronchodilators to enhance the efficacy. Before using the drug, the patient's lung function, cardiovascular status and past medication history need to be assessed to ensure safety.

When using exefentine, attention should be paid to individualized dose adjustment and adverse reaction monitoring. Common adverse reactions include mild cough, throat irritation or dry mouth, and are generally well tolerated. For patients with severe cardiovascular disease, it should be used with caution under the guidance of a doctor, and heart rate and blood pressure should be monitored regularly. In addition, patients should avoid concurrent use of other drugs with strong cardiovascular effects to reduce potential risks. In short, Ohtuvayre provides a new treatment option for patients with COPD through dual mechanisms, which can improve lung function while improving quality of life.

Reference materials:https://www.drugs.com/